# Slayback Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/slayback-pharma

- Industry: Pharmaceuticals
- Headquarters: Princeton, US
- Website: www.slayback-pharma.com
- Total disclosed funding: $85M
- Latest round: Series B (Jan 6, 2020)
- Investors on record: 2

## About

Based in the US, Slayback Pharma, LLC develops innovative pharmaceutical products focused on addressing unmet medical needs in specialty markets.Slayback Pharma, LLC specializes in pharmaceutical development and has been operational since its founding in 2011 in Princeton, US. The company was acquired by Azurity Pharmaceuticals from KKR and Everstone Capital Partners in September 2023, enabling further innovation. Throughout its operation, it has completed 4 deals, with its most recent deal occurring on September 27, 2023, during a Series B funding round where it raised USD 50.00 mn, which is the total amount raised to date.Slayback Pharma provides a diverse range of pharmaceutical products designed for niche patient populations. The company’s offerings include over 30 marketed brands across therapeutic areas such as Allergy, Oncology, and Respiratory. Notable products feature XIFYRM™ (meloxicam injection), an FDA-approved NSAID for managing moderate-to-severe pain with a once-daily IV dosing regimen. Its products are marketed in over 50 countries, catering to healthcare providers and specialty pharmacies.Slayback Pharma generates revenue through direct sales of its pharmaceutical products and partnerships with healthcare providers. Its pricing aligns with industry standards and reflects the value provided in managing health conditions, primarily through the sale of branded medications aimed at improving patient outcomes.The acquisition by Azurity Pharmaceuticals is set to facilitate the launch of multiple innovative drug products. Slayback Pharma aims to expand its presence in new geographic markets, focusing on reaching underserved regions by leveraging the recent funding secured in the Series B round. The specific strategies for product development and market expansion will be supported by the USD 50.00 mn raised, allowing the company to enhance its product pipeline and broaden its market reach.

## Funding rounds

- Series B, Jan 6, 2020, $50M — Everstone Group
- Series A, Dec 29, 2016, $35M — KKR

## Investors

- KKR (https://capitalatlas.ai/funds/kkr) — Series A
- Everstone Group (https://capitalatlas.ai/funds/everstone-group) — Series B